Skip to main content

Table 1 Tamoxifen vs. aromatase inhibitors in the neoadjuvant setting

From: Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women—a literature review and proposed guidelines

Study Duration (months) Dose (mg/day) No. of patients Study outcomes Assessment
P024 Trial Eiermann et al. 2001 [59] 4 Letrozole 2.5 or tamoxifen 20 324 1. pCR: 1.3% letrozole; 1.8% tamoxifen
2. ORR (clinical palpation): 55% letrozole; 36% tamoxifen (p < 0.0001). ER+subgroup: 60% letrozole; 41% tamoxifen.
3. BCS: 45% letrozole; 35% tamoxifen (p = 0.022)
Monthly clinical palpation and ultrasound. Mammography at baseline and prior to surgery.
PROACT Cataliotti et al. 2006 [60] 3 Anastrozole 1 or tamoxifen 20 ± NCT 451 1. pCR: NR.
2. ORR (clinical palpation): 49.7% anastrozole; 39.7% tamoxifen (p > 0.5, NET only)
3. BCS: 43% anastrozole; 30.8% tamoxifen (p = 0.04, NET only)
Ultrasound and caliper measurements at baseline and 3 months.
IMPACT Smith et al. 2005 [19] 3 Anastrozole 1 or tamoxifen 20 or combination 330 1. pCR: NR.
2. ORR (clinical palpation): 37% anastrozole; 36% tamoxifen; 39% combination (p = 0.87)
3. BCS: 44% anastrozole; 31% tamoxifen; 24% combination (p = 0.23, mastectomy at baseline)
Clinical caliper measurements and ultrasound at baseline, 2, 6 and 12 weeks.
Akashi-Tanaka et al. 2007 [63] 5 (Anastrozole) or 4 (Tamoxifen) Anastrozole 1 or tamoxifen 20 45 1. pCR: not reported.
2. ORR (clinical palpation): 76.5% anastrozole; 46.4% tamoxifen
3. BCS: not reported.
Monthly clinical assessment.
Semiglazov et al. 2005 [64] 3 Exemestane 25 or tamoxifen 20 151 1. pCR: 2.6% exemestane; 2.7% tamoxifen
2. ORR (clinical palpation): 76.3% exemestane; 40% tamoxifen (p = 0.05)
3. BCS: 36.8% exemestane; 20% tamoxifen (p = 0.05)
Not reported.
  1. BCS breast-conserving surgery, pCR pathological complete response, ORR objective response rate, CR complete response, PR partial response, NR not reported. See Additional file 1, Table S2 for definitions